Clinical Trial

Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC

Name: Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC — clinical trial record (NCT06856278)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.

Trial Details

NCT Number	NCT06856278
Lead Sponsor	Zhejiang Provincial People's Hospital
Conditions	Anaplastic Throid Carcinoma
Enrollment	30 participants
Start Date	2025-02-22
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-03-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-04